RxDoctor Payments Data

Cordelia Uddoh, MD

Ophthalmology · Philadelphia, PANPI 1821179243

Payments from drug & device makers

$458in general payments, 2019–2025

Across 23 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$158
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$105
  • Aerie Pharmaceuticals, Inc.$46
  • Bausch & Lomb Americas Inc.$39
  • Sun Pharmaceutical Industries Inc.$35
  • Amgen$21
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$33673%
  • Education$409%
  • Gifts$8218%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$458 in reported general payments places this provider in the 30th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$135,080
Medicare patients
232
Services billed
1,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine45$64,498
RocklatanNetarsudil Mesylat/Latanoprost70$56,620
SimbrinzaBrinzolamide/Brimonidine Tart71$27,574
XiidraLifitegrast19$27,372
LumiganBimatoprost33$24,157
Brimonidine Tartrate186$22,203
Timolol Maleate194$21,584
Cyclosporine24$16,036
Travoprost58$15,057
RhopressaNetarsudil Mesylate24$14,355
Prednisolone Acetate260$12,610
Loteprednol Etabonate30$11,225
Lotemax SmLoteprednol Etabonate35$10,259
CombiganBrimonidine Tartrate/Timolol18$8,697
VyzultaLatanoprostene Bunod12$8,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$158$97,35196 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$46$70,97594 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$39$35,38931 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm$105$21,48465 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →